trending Market Intelligence /marketintelligence/en/news-insights/trending/Yh7wXKNmizUQWnxR9QP_Qw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Allergan Q2 profit down 4.3%; 2019 revenue guidance raised

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Allergan Q2 profit down 4.3%; 2019 revenue guidance raised

Allergan PLC said its non-GAAP performance net income attributable to shareholders for the second quarter came to $4.38 per share, down from $4.42 per share in the year-ago period.

The S&P Global Market Intelligence consensus normalized EPS estimate for the quarter was $4.34.

The Dublin-based drugmaker said non-GAAP performance net income attributable to shareholders totaled $1.44 billion, a decline of 4.3% from $1.51 billion in the year-earlier period.

Net revenue totaled $4.09 billion, compared with $4.12 billion in the year-earlier period, and research and development expenses fell 34.7% year over year to $450.0 million from $689.2 million.

The GAAP net loss attributable to ordinary shareholders totaled $1.76 billion, or a loss of $5.37 per share, compared with a loss of $472.5 million, or a loss of $1.39 per share, in the year-earlier period.

Year-to-date through June 30, the company's non-GAAP performance net income attributable to shareholders totaled $8.17 per share, compared with $8.16 per share in the prior-year period.

Non-GAAP performance net income attributable to shareholders was $2.71 billion, a decrease from $2.81 billion in the prior-year period.

Year-to-date net revenue declined year over year to $7.69 billion from $7.80 billion.

The company said GAAP net loss attributable to ordinary shareholders came to a loss of $4.17 billion, or a loss of $12.63 per share, in the year to June 30, compared with a loss of $805 million, or a loss of $2.39 per share, in the prior-year period.

Guidance

Allergan, which is being acquired by AbbVie Inc. in an $84.2-billion deal, raised its GAAP revenue guidance for 2019. The company said it expects GAAP total net revenues in the range of $15.43 billion to $15.63 billion for the full year, an increase from previous guidance in the range of $15.13 billion to $15.43 billion.

The company expects non-GAAP net income per share at $16.55 for the full year, steady with the previous guidance.

The S&P Global Market Intelligence consensus normalized EPS estimate for the full year is $16.74.